Using PSURs for Benefit-Risk Evaluation in Pharmacovigilance

Periodic Safety Update Reports (PSURs) are critical tools for assessing the benefit-risk balance of a pharmaceutical product during its post-marketing lifecycle. They serve not only to report cumulative safety data but also to contextualize these findings against the known benefits of the drug. A well-prepared PSUR enables sponsors and regulators to make informed decisions about product labeling, continued marketing, or necessary risk mitigation strategies. This guide explains how to effectively use PSURs for benefit-risk evaluation in compliance with global regulatory expectations.

What is Benefit-Risk Evaluation?

Benefit-risk evaluation is a core function of pharmacovigilance that compares the therapeutic benefits of a drug to its associated risks. These assessments are dynamic and evolve over time with new clinical data, adverse event reports, and real-world usage.

As per the EMA, the benefit-risk assessment is central to determining whether a drug’s market authorization should be maintained, modified, or withdrawn. PSURs are the structured vehicles through which this assessment is regularly updated and communicated.

How PSURs Enable Benefit-Risk Assessments

The PSUR provides a systematic framework to integrate:

• New and cumulative adverse event data
• Post-marketing clinical studies
• Updated exposure estimates
• Labeling changes and regulatory decisions
• Comparative safety data vs similar products

Through this integration, sponsors and regulators can objectively reassess the balance between the benefits and risks of a product.

Relevant Sections of PSUR for Benefit-Risk Evaluation

1. Section 6: Summary of Safety Concerns
2. Section 7: Signal Evaluation
3. Section 8: Integrated Benefit-Risk Analysis
4. Section 9: Conclusions and Actions

These sections must align in content and tone. For example, new signals in Section 7 should be reflected in the updated benefit-risk analysis in Section 8, along with justifications for any proposed changes to the risk management plan (RMP).

Quantitative and Qualitative Approaches

Benefit-risk evaluations can be presented in two main formats:

1. Qualitative Assessment

• Uses expert medical judgment
• Describes how reported risks affect the overall safety profile
• Justifies whether the risk alters the favorable benefit-risk balance

2. Quantitative Models

• Applies statistical models such as Number Needed to Treat (NNT) and Number Needed to Harm (NNH)
• Used for chronic or high-risk products where risk is harder to interpret qualitatively
• Visual tools like benefit-risk grids, value trees, and forest plots

These tools can be implemented using software approved under validation master plans to ensure audit-ready outputs.

Incorporating Real-World Data in Benefit-Risk Analysis

PSURs should not rely solely on clinical trial results. They must integrate real-world data (RWD), including:

• Spontaneous AE reporting
• Product usage trends
• Off-label usage reports
• Stability testing results indicating quality-linked safety issues
• Patient feedback and compliance patterns

This multi-dimensional approach offers a richer, more realistic picture of benefit-risk balance.

Case Example: Benefit-Risk Reevaluation in Antidiabetics

Imagine a company marketing a novel antidiabetic agent detects an increased frequency of pancreatitis reports. In the latest PSUR:

• The company identifies the signal under Section 7
• Reviews severity, causality, and reversibility of the AE
• Compares data with similar agents on the market
• Updates Section 8 to reflect a slight reduction in the benefit-risk balance
• Proposes a label update and monitoring guideline in Section 9

Such integration demonstrates proactive pharmacovigilance and aligns with GMP compliance.

Best Practices for Benefit-Risk Evaluation in PSURs

• Ensure consistency between safety signal evaluations and benefit-risk narrative
• Use tabular presentations to summarize key risks and corresponding benefits
• Highlight any changes from the previous PSUR cycle
• Justify retention or modification of labeling, RMP, or product status
• Document internal benefit-risk decisions using SOP-compliant formats

Common Pitfalls to Avoid

• Over-reliance on clinical trial data and neglecting real-world signals
• Failure to address newly emerging risks in context of benefits
• Inconsistencies between different PSUR sections
• Unjustified conclusions lacking signal analysis depth

Regulatory Expectations

• EMA: Emphasizes integrated and transparent benefit-risk summaries
• USFDA: Expects direct linkage between signals and risk mitigation plans
• CDSCO: Requires benefit-risk narratives to justify product continuation

Failure to address benefit-risk thoroughly can delay PSUR acceptance or trigger additional post-marketing commitments.

Conclusion

Benefit-risk evaluation within a PSUR is not a checkbox task—it is a central pillar of ongoing pharmacovigilance. A structured, evidence-based benefit-risk section demonstrates a sponsor’s commitment to patient safety and regulatory transparency. By combining medical expertise with statistical tools, real-world data, and a consistent narrative, PSURs can effectively convey the evolving safety landscape of a product and support sound regulatory decision-making.

Understanding the Purpose and Structure of a PSUR in Clinical Trials

In clinical trials and post-authorization safety monitoring, a Periodic Safety Update Report (PSUR) is a critical regulatory document that compiles cumulative safety data to evaluate the benefit-risk profile of a medicinal product. Globally harmonized under ICH E2C (R2), the PSUR helps sponsors maintain ongoing pharmacovigilance compliance, detect emerging signals, and communicate risk trends to regulatory authorities like the EMA or USFDA. This tutorial explores the core components, format, and strategic role of PSURs in clinical development and beyond.

What Is a PSUR and Why Is It Important?

The Periodic Safety Update Report is a structured document that summarizes all relevant safety data of an investigational or marketed drug at defined intervals, often every six months or annually. The PSUR aims to:

• Provide a cumulative assessment of the drug’s safety profile
• Identify new safety signals or trends over time
• Evaluate risk minimization measure effectiveness
• Support regulatory decisions for continued development or label changes
• Ensure synchronization between global regulatory expectations

While initially more common in the post-marketing phase, PSURs are increasingly integrated into advanced-stage clinical trial pharmacovigilance planning.

Regulatory Foundation and PSUR Periodicity

As per ICH E2C(R2) and EMA’s Module VII-GVP, PSURs must be submitted periodically for authorized medicinal products. Clinical trial sponsors may be required to submit similar cumulative safety summaries during investigational phases.

Typical PSUR Timelines:

• Initial Post-Authorization: Every 6 months for first 2 years
• Thereafter: Annually for 3 more years
• After Year 5: Every 3 years unless otherwise specified

The frequency can vary depending on country-specific regulations and risk classification of the product.

PSUR vs. PBRER

The term PSUR is often used interchangeably with PBRER (Periodic Benefit-Risk Evaluation Report). While both documents share similar objectives, the PBRER format emphasizes a more comprehensive benefit-risk evaluation aligned with ICH E2C(R2). In the EU, the PBRER is the required format for all PSUR submissions.

In practice, most companies use the PBRER format to fulfill PSUR requirements globally.

Core Structure of a PSUR (PBRER Format)

The PSUR is organized into clearly defined sections. Below is a breakdown of the standard structure:

1. Introduction

Defines the scope, time interval (Data Lock Point), and product summary, including formulation and indications.

2. Worldwide Marketing Authorization Status

Lists all countries where the product is authorized, suspended, or withdrawn, and reasons for any changes.

3. Actions Taken for Safety Reasons

Summarizes regulatory actions based on safety signals, including labeling updates or risk mitigation changes.

4. Changes to Reference Safety Information (RSI)

Describes changes made to the Investigator’s Brochure or Company Core Safety Information (CCSI).

5. Estimated Exposure and Usage Patterns

• Clinical trial exposure by indication and population
• Post-marketing exposure (patient-year estimates)

6. Data in Summary Tabulations

Aggregate safety data across spontaneous reports, literature, and clinical trials, stratified by seriousness and outcome.

7. Summaries of Significant Individual Case Histories

Detailed narratives of key adverse events (AEs), especially fatal or unexpected cases.

8. Signal and Risk Evaluation

Assessment of new, ongoing, or closed signals, with impact on benefit-risk balance.

9. Benefit-Risk Evaluation

Integrated discussion on the evolving benefit-risk profile with scientific justification.

10. Conclusions and Actions

Final assessment and proposed regulatory actions (if any).

Supporting appendices include line listings, literature references, and exposure data.

Data Sources Used in PSURs

PSURs gather safety information from multiple data streams:

• Spontaneous adverse event reporting systems
• Clinical trial databases (CDMS)
• Medical literature (e.g., PubMed, Embase)
• Regulatory databases (e.g., EudraVigilance)
• Stability studies impacting product safety profile
• Ongoing PASS and registries

The comprehensiveness of data significantly influences the accuracy of benefit-risk evaluations.

Common Challenges and Best Practices

Generating a robust PSUR requires cross-functional collaboration between pharmacovigilance, regulatory, clinical, and biostatistics teams. Challenges include:

• Inconsistent data capture across regions or systems
• Late signal detection due to inadequate AE coding
• Version control issues in RSI and labeling history
• Insufficient narrative detail in individual case reports

Best practices to improve PSUR quality include:

1. Automating data aggregation from safety databases
2. Standardizing template and writing SOPs from Pharma SOP templates
3. Conducting regular quality reviews and mock audits
4. Integrating statistical analysis for trend evaluation
5. Including KPIs to assess PSUR impact over time

Submission and Review Timelines

PSURs are submitted electronically through platforms such as the EMA’s EVMPD or FDA’s ESG. Deadlines are defined by the EU Reference Date (EURD) list or by national regulators.

Upon submission, authorities may:

• Accept the report without action
• Request clarifications or additional data
• Mandate changes to SmPC, labeling, or RMP

Maintaining a clear audit trail of submission dates, changes, and follow-up ensures smooth compliance.

Conclusion

The PSUR serves as a cornerstone of pharmacovigilance documentation, enabling a dynamic understanding of product safety in clinical and real-world contexts. By following ICH E2C(R2) standards and leveraging best practices in data collection and narrative analysis, pharmaceutical companies can ensure their PSURs are not only regulatory compliant but also meaningful tools for proactive safety monitoring. Whether in clinical trials or post-marketing phases, a well-structured PSUR aligns all stakeholders in the collective mission of protecting patient health.